Effect of Valsartan on Systemic Right Ventricular Function A Double-Blind, Randomized, Placebo-Controlled Pilot Trial

T van der Bom, MM Winter, BJ Bouma, M Groenink, HW Vliegen, PG Pieper, APJ van Dijk, GT Sieswerda, Jolien Roos - Hesselink, AH Zwinderman, BJM Mulder

Research output: Contribution to journalArticleAcademicpeer-review

133 Citations (Scopus)


Background-The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. Methods and Results-We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindica Conclusions-There was no significant treatment effect of valsartan on right ventricular ejection fraction, exercise capacity, or quality of life. Valsartan was associated with a similar frequency of significant clinical events as placebo. Small but significant differences between valsartan and placebo were present for change in right ventricular volumes and mass. Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN52352170. (Circulation. 2013; 127: 322-330.)
Original languageUndefined/Unknown
Pages (from-to)322-+
Issue number3
Publication statusPublished - 2013

Cite this